Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 6/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20313565 | 0.93 | PTPN11 (0.36) | RARBTSHRPTPN11CNR2CNR1 | |
| SCHEMBL19855967 | 0.91 | MOGAT2 (0.31) | — | |
| SCHEMBL20313570 | 0.90 | RARB (0.36) | RARBTSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL20313568 | 0.89 | RARB (0.41) | RARBMEN1ALDH1A1KMT2APTPN11 | |
| SCHEMBL19856077 | 0.89 | TSHR (0.38) | TSHRMEN1ALDH1A1KMT2ACNR2 | |
| SCHEMBL19854220 | 0.87 | RARB (0.39) | RARBMEN1ALDH1A1KMT2APTPN11 | |
| SCHEMBL20313567 | 0.86 | RARB (0.41) | RARBMEN1ALDH1A1KMT2APTPN11 | |
| SCHEMBL19856082 | 0.86 | CNR2 (0.38) | RARBTSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL20313574 | 0.85 | CSF3R (0.34) | PPARG | |
| SCHEMBL20313509 | 0.85 | CNR2 (0.37) | RARBTSHRMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | RARB 3791/4885TSHR 4050/4885MEN1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.